Anti-IL-17, Anti-IL-23 Rxs Show Sustained Psoriasis Control
Both an approved anti-IL-17 therapy and an experimental oral anti-IL-23 therapy appeared to achieve relatively undiminished rates of psoriasis control in extension studies.
Source: medscape.com